Buscar
Bone Biologics Corp
BBLGAñadir a la lista de seguimiento
0.850USD
-0.010-1.17%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
1.53MCap. mercado
PérdidaP/E TTM
Más Datos de Bone Biologics Corp Compañía
Bone Biologics Corporation is a clinical-stage developer of orthobiologic products for spine fusion markets. The Company is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.
Información de Bone Biologics Corp
Símbolo de cotizaciónBBLG
Nombre de la empresaBone Biologics Corp
Fecha de salida a bolsaNov 27, 2015
Director ejecutivoFrelick (Jeffrey)
Número de empleados2
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 27
Dirección2 Burlington Woods Dr Ste 100
CiudadBURLINGTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal01803-4551
Teléfono17815524452
Sitio Webhttps://www.bonebiologics.com/
Símbolo de cotizaciónBBLG
Fecha de salida a bolsaNov 27, 2015
Director ejecutivoFrelick (Jeffrey)
Ejecutivos de Bone Biologics Corp
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jeffrey Frelick
Mr. Jeffrey Frelick
President, Chief Executive Officer
President, Chief Executive Officer
360.00
+0.28%
Ms. Deina H. Walsh, CPA
Ms. Deina H. Walsh, CPA
Chief Financial Officer
Chief Financial Officer
313.00
--
Mr. Bruce Stroever
Mr. Bruce Stroever
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Siddhesh Rajendra (Sid) Angle, Ph.D.
Dr. Siddhesh Rajendra (Sid) Angle, Ph.D.
Independent Director
Independent Director
--
--
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
--
--
Mr. Phillip T. Meikle
Mr. Phillip T. Meikle
Independent Director
Independent Director
--
--
Mr. Jody Cain
Mr. Jody Cain
Investor Relation
Investor Relation
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jeffrey Frelick
Mr. Jeffrey Frelick
President, Chief Executive Officer
President, Chief Executive Officer
360.00
+0.28%
Ms. Deina H. Walsh, CPA
Ms. Deina H. Walsh, CPA
Chief Financial Officer
Chief Financial Officer
313.00
--
Mr. Bruce Stroever
Mr. Bruce Stroever
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Siddhesh Rajendra (Sid) Angle, Ph.D.
Dr. Siddhesh Rajendra (Sid) Angle, Ph.D.
Independent Director
Independent Director
--
--
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
--
--
Mr. Phillip T. Meikle
Mr. Phillip T. Meikle
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Bone Biologics Corp?
Los cinco principales accionistas de Bone Biologics Corp son: Mr. Jeffrey Frelick
¿Cuántas instituciones poseen acciones de Bone Biologics Corp (BBLG)?
A fecha de 2026Q1, 17 instituciones poseen acciones de Bone Biologics Corp, con un valor de mercado combinado de aproximadamente 58.41K, lo que representa el 3.25% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 22009.00.